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Abstract
Background: Access to patient level datasets from clinical trial sponsors continues to be an important topic for the
Pharmaceutical Industry as well as academic institutions and researchers. How to make access to patient level data
actually happen raises many questions from the perspective of the researcher.
Methods: Patient level data access models of all major pharmaceutical companies were surveyed and
recommendations made to guide academic researchers in the most efficient way through the process of
requesting and accessing patient level data.
Results: The key considerations for researchers covered here are finding information; writing a research proposal to
request data access; the review process; how data are shared; and the expectations of the data holder. A lot of
clinical trial information is available on public registries and so these are great sources of information. Depending
on the research proposal the required information may be available in Clinical Study Reports and therefore patient
level data may not need to be requested. Many data sharing systems have an electronic form or template but in
cases where these are not available the proposal needs to be created as a stand-alone document outlining the
purpose, statistical analysis plan, identifying the studies for which data are required, the research team members
involved, any conflicts of interest and the funding for the research.
There are three main review processes - namely having an internal review board, external review board selected by
the data holder or an external review board selected by a third party. Data can be shared through Open access i.e.
on a public website, direct sharing between the data holder and the researcher, controlled access or the data
holder identifies a contract organization to access the data and perform the analyses on behalf of the researcher.
The data that are shared will have accompanying documentation to assist the researcher in understanding the
original clinical trial and data collection methods. The data holder will require a legally binding data sharing
agreement to be set up with the researcher. Additionally the data holder may be available to provide some
support to the researcher if questions arise.
Conclusion: Whilst the benefits and value of patient level data sharing have yet to be fully realised, we hope that
the information outlined in this article will encourage researchers to consider accessing and re-using clinical trial
data to support their research questions.
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Introduction
This article is one of a series of articles developed by the
EFSPI/PSI Data Sharing Working Group. The working
group consists of medical research statisticians from
both pharmaceutical industry and academia. It was set
up with the intention of providing knowledge and in-
sights regarding the practical challenges and opportun-
ities of accessing clinical trial data for re-analysis or
secondary research purposes.
The intended audience for this article comprises aca-
demic researchers who would like to access patient level
data from industry sponsored clinical trials. The article
provides a perspective of the activities that happen “behind
the scenes” to enable such data sharing to be achieved as
well as informing the researcher as to what to expect along
the data request process. Figure 1 outlines the seven steps
involved in requesting and accessing patient level datasets.
This article outlines each of the 7 steps in turn.
The access and the value of re-use of data from clin-
ical trials has been the topic of much debate in recent
years [1, 2]. This public and media debate culminated in
the European Medicines Agency (EMA) publishing a draft
policy on data transparency in 2013 [3], the development
of the EFPIA/PhRMA principles [4] for pharmaceutical in-
dustry bodies in the Europe and the USA and subsequently
the EMA Policy on clinical data for medicinal products for
human use in October 2014 [5]. The EMA Policy came
into effect on the 1st January 2015. The policy does not in-
clude any commitments regarding access to patient level
datasets via the EMA, or regulatory documents filed before
this date. Many clinical trial funders and sponsors have
committed to sharing clinical trial documentation for
drugs that are approved after the 1st January 2014 and in
many cases also patient level datasets under certain condi-
tions. These conditions include steps to respect patient
confidentiality and minimise the risks of re-identification
of trial participants. This approach is now widely accepted
and supported by statistical communities [6].
The European and American industry bodies repre-
senting research-based pharmaceutical companies pub-
lished the EFPIA/PhRMA principles in 2013 stating that































Fig. 1 Key steps in the request and access of patient level data. Each step is referenced and described in more detail in the text
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public health through responsible sharing of clinical trial
data (see Table 1 for details). In tandem, many pharmaceut-
ical companies have published their Data Sharing policies.
Some have implemented the EFPIA/PhRMA principles as
stated, whilst other companies have chosen to broaden the
scope of clinical trial data to be shared [7].
Patient Data sharing in the era of data transparency is
relatively new and processes and tools will continue to
evolve. The Institute of Medicine (IoM) [8] the Well-
come Trust [9] the Multi-Regional Clinical Trials
(MRCT) unit at Harvard [10] and Tudur Smith et al. on
behalf of the Medical Research Council (MRC) Network
of Hubs for Trials Methodology [11] all address the
challenges and potential principles for future wide-scale
patient level data sharing. The objective of this article is
to provide practical information to researchers regarding
identifying datasets to be requested, the dataset request
process, expectations and roles of the study sponsor and
expectations of the researcher.
This article will focus on the patient level dataset shar-
ing commitments of clinical trial sponsors (i.e. the elec-
tronic datasets created during the course of a clinical
trial) and the available methods for third party access to
these datasets. It will also give some guidance as to how
data requesters should seek access. Access to clinical
trial information as summarised within Clinical Study
Reports (CSR) will not be addressed in this article. How-
ever, we note that Clinical Study Reports provide richer
information than that provided in a journal publication.
Table 2 provides an outline of the end to end process for
requesting access to patient level datasets. The following
sections of this Discussion document will address each
of these steps in turn.
Terminology and definitions
For the purposes of this article we will use the following
definitions for the terms “Data”, “Data Holder”,
“Researcher” and “Anonymised/De-identified” data.
“Data” has many meanings in the context of clinical
trial reporting. It can be used to describe publications,
clinical study reports, summary statistics and patient
level data. Within this article all references to “data” will
mean electronic patient level datasets (PLD). Where
other data types are mentioned in the text, they will be
referred to with an accompanying description.
“Data Holder” will be used to define any organisation
that conducts clinical trials and has the rights to share
the database of the electronic patient level data for that
study. This could include pharmaceutical companies,
biotech companies, medical device companies, academic
groups and medical charities. We do not consider Con-
tract Research Organisations (CROs) that are paid to
conduct studies, collect and analyse clinical trial data on
behalf of others to be Data Holders.
“Researcher” will be used to define any individual or
group who seeks access to patient level data in order to
address a specific research question. Researchers are ex-
ternal to the Data Holder’s organisation and could be ac-
ademics employed in the public or private sector.
“Anonymised/de-identified” data – Guidance on imple-
mentation of the EMA policy 0070 [12] defines anonymi-
sation as “the process of rendering data into a form which
does not identify individuals and where identification is
not likely to take place”, and anonymised/de-identified
data as “data in a form that does not identify individuals
and where identification through its combination with
other data is not likely to take place”.
The Health Insurance Portability and Accountability
Act (HIPAA) [13] defines “de-identified protected health
information’ as ‘Health information that does not iden-
tify an individual….there is no reasonable basis to believe
that the information can be used to identify an
individual….”.
Note that terms ‘de-identification’ and ‘anonymisation’
are often used interchangeably in different contexts in
the literature.
Table 1 Summary of the EFPIA/PhRMA Principles for Responsible Clinical Trial Data Sharing
1. Enhancing data sharing with researchers On request from qualified medical and scientific researchers, companies will provide protocols, reports
and patient-level clinical trial data for medicines that have been approved in both the EU and US.
Each company will establish a scientific review board that will include scientists and/or healthcare
professionals who are not employees of the company.
Access will be consistent with patient informed consent and safeguarding privacy.
2. Enhancing public access to clinical study
information
Companies will make available synopses of CSRs submitted to US and European regulatory authorities
from 1 Jan 2014.
3. Sharing results with patients who
participate in clinical trials
Companies will work with regulators to adopt mechanisms for providing a factual summary of clinical
trial results and make the summaries available to research participants.
4. Certifying procedures for sharing clinical
trial information
Companies will certify on a publicly available web site that they have established policies and
procedures to implement these data sharing commitments.
5. Reaffirming commitments to publish
clinical trial results
Results from all phase 3 clinical trials and any clinical trial results of significant medical importance
should be submitted for publication, whether positive or negative, including results from discontinued
development programs.
Sudlow et al. BMC Medical Research Methodology 2016, 16(Suppl 1):73 Page 25 of 43
“Anonymisation/De-identification” of data is the
process by which the Data Holder will edit the patient
level data to reduce the risk of patient re-identification.
This can be achieved through removing, grouping or
amending certain data fields (e.g. remove date of birth)
and grouping patients (e.g. >89 years of age.
A “Clinical Study Report (CSR)” is the term used in in-
dustry for the report generated from a clinical trial. It
contains details of the protocol design, a comprehensive
overview of the analysis and results and interpretation
and conclusions drawn from the data. The CSR is the
document that is used to communicate the outcome of
the trial to health authorities. A typical CSR (including
all appendices) can be in excess of 1000 pages.
Getting started
The development of a research proposal requesting ac-
cess to patient level datasets is not without effort on the
Researcher’s part. Time will be needed by the Data
Holder to review the feasibility of the request, facilitate
the scientific review of the proposal and de-identify the
datasets and prepare the accompanying documentation.
Prior to embarking on the process of writing a research
proposal for datasets and submitting it to the Data
Holder, the Researcher should consider whether the
information within the CSR for the trial would be suffi-
cient to answer the research question of interest. For ex-
ample, when conducting a meta-analysis using summary
data (rather than individual patient data) access to the
CSR may be sufficient. Clinical Study Reports contain a
richness of information about a clinical trial – including
secondary, exploratory and sensitivity analyses that will
not have been included within a clinicaltrials.gov posting
or a journal article [14]. Clinical Study Reports can be
obtained in some cases via requests directly to the spon-
sor company or through the EMA freedom of informa-
tion policy. The EMA route should only be used after all
other efforts at collaboration have been exhausted and
would only be relevant to studies that have been in-
cluded as part of an European Union (EU) regulatory
review.
Accessing a copy of the CSR may be quicker than
gaining access to the patient level datasets. If the CSR
does not contain the information needed, it will still help
inform the Researcher of many more details regarding
the trial and may assist in the development of a more
complete research proposal for patient level data. If a
number of studies (either from one Data Holder or more
than one) are of interest, the CSRs will be a useful indi-
cation regarding how compatible these trials are likely to
be for dataset pooling.
Step 1: How can a researcher find out which studies have
been conducted that fit the research question?
This article assumes that the researcher is familiar with
performing literature searches and has identified a set
of clinical trials that match their search criteria (e.g. a
specific drug, class of drugs or medical condition).
Overviews and discussions regarding performing robust
literature reviews have been published and the
Cochrane Collaboration’s manual is a valuable source of
advice [15].
Most clinical trials nowadays are registered on public
registries prior to the first patient being recruited and
many will have summary results posted within 1 year of
the study report being completed. These registries in-
clude clinicaltrials.gov [16] for, at minimum, trials with
centres in the USA or a drug that was manufactured in
the USA. For trials run in the EU, the EUdraCT registry
[17] will be a source of useful summary information.
The World Health Organisation (WHO) has the Inter-
national Clinical Trials Registry Platform (CTRP) [18].
However results postings on registries are still not 100 %
complete [19] and the issue of clinical trial “discoverabil-
ity” continues to be a challenge [20].
The unique NCT identifier generated for each study
posted on clinicaltrials.gov is also a very useful piece of
information to identify a study as some journals require
this to be quoted in articles relating to the study. The
Table 2 Typical End to End Process for requesting Patient Level
Data (PLD)
Step Considerations
1. Develop PLD research
proposal
What studies have been conducted?
Who is the Data Holder?
Do they have a data access policy and is
this study available?
Could access to the CSR help inform the
research proposal development?
Does the Data Holder have a specific
template for the research proposal?
2. Submission and review
of research proposal
Who will review it? Independent review
panel or within the Data Holder
organisation?
Data Holder’s expectations for sharing data
Researcher’s expectations for accessing data
3. Dataset preparation for
external sharing
How will the data be shared? (open,
secure system or other?)
Data Sharing Agreement review and sign-off
Data de-identification principles
4. Analysis Data package contents
Opportunities to ask questions
5. Reporting / Publication Data Holder’s expectations regarding
publication of the results.
Referencing the data source
Any commitments to share the results/
manuscript prior to publication?
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study sponsor will have a link between the NCT number
and their in-house clinical trial naming convention.
The drug approval labels for products can be a useful
source of information regarding the studies that were
conducted in order for the product to be granted a li-
cence. Both the FDA and EMA have detailed websites
[21, 22] where a researcher can view and download these
documents. One limitation of the drug label is that the
study unique identifier is inconsistently included in these
documents. Some drug labels substitute “Study 1”,
“Study 2” and “Study 3” (for example) as the names for
the pivotal studies. In these situations, a researcher will
need to try and link the study characteristics (objectives,
patient numbers per arm) with a disclosures database
posting to deduce the study identifier. For example in
the US registry clinicaltrials.gov, there is a field for
“other study ID number” and this may also be inform-
ative in identifying the study of interest.
Another area for confusion is the naming of studies.
All trials that are run by pharmaceutical companies will
have a unique, internal study identifier. This identifier is
usually made up of a series of letters and numbers (every
company has their own approach to this). It is usually
this identifier that is used internally to store all the infor-
mation regarding a study and so is the most effective
name that a researcher can use when interacting with an
organisation. Sometimes studies are also given a name
(e.g. TENDER). However the name can be used incon-
sistently to tag information and company databases do
not always index on the name. Most articles written
about industry sponsored trials rarely include the unique
internal identifier, so this will add to the challenge of
dataset identification. We recommend that the re-
searcher includes as much information as possible to
help facilitate identifying the relevant study data.
How to find out which organisation is the data holder for a
trial?
The public registry posting for a trial contains details of
the “sponsor” – this is a likely to be the Data Holder for
the trial and should be a good place to identify who
should be approached for access to the study data.
There are also situations where companies have trans-
ferred products to other companies, so the original study
sponsor as listed on the registries is no longer the Data
Holder. Examples of these types of changes are recent
divestment of GSK’s oncology products to Novartis [23].
In such situations we recommend that the new licence
holder is contacted.
Once the Data Holder has been identified, the re-
searcher will need to find out if the study is available
for data access. Access will generally only be avail-
able for studies that have completed recruitment and
the primary analysis has been reported or the trial
was terminated. Studies still recruiting will be out of
scope.
Which studies are in scope for data sharing?
Data Holders will often provide information regarding
access to clinical trial documentation and data via their
company websites. These can generally be found by
searching “data transparency” or “data sharing” on their
site. Articles have been published summarising the data
sharing policies of pharmaceutical and biotech compan-
ies [7, 24], but in the rapidly changing data sharing land-
scape these will soon become out of date.
There is no cross-pharma standard regarding the shar-
ing of data from historical studies and the phases of clin-
ical trials to be included. Sponsor commitments can
range from all phases (phase 1 through to the post mar-
keting studies) to only the phase 3 pivotal studies. Some
sponsors have limited their dataset access to drugs ap-
proved since 1st January 2014 whilst others are willing
to provide data from earlier filings and for terminated
products that never made it through to regulatory ap-
proval. The reasons for these differences are varied; they
could be based on the text used within the informed
consent process historically, whether the metadata for
an historic database is easily accessible and whether the
creation of a usable data navigation package for the re-
searcher is feasible. Data, programs and dataset docu-
mentation generated for trials that were conducted
many years ago may be held on old, archived servers
and analysis software updates may mean that the ana-
lysis code is not easily executable. These factors may
mean that the process of dataset anonymization and
dataset sharing is difficult for some older studies.
Generally companies have a pre-requisite that the drug
and indication must be approved in both the US and EU
and that a certain amount of time has passed since the
CSR was completed before data is available for sharing
with researchers. This time lag is to enable the principal
investigators who ran the study sufficient time to publish
their work on the study. Some companies require that
the results have been published in a journal before any
patient level data sharing is possible whilst others base
this around a time period (e.g. 18 months after the CSR
was completed) [8]. For older studies the decision to
grant access to data and the decision to publish may
have been handed over to an external Trial Steering
Committee (TSC). In these situations the Data Holder
will not be able to share data without the Steering
Committee’s approval. In the survey conducted by
Conroy et al. [25] 42 % of TSCs had a role in determin-
ing additional publications to the main report and data
sharing.
Some sponsors will provide lists of trials that are
available for patient level data requests (e.g.
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clinicalstudydatarequest.com (CSDR.com) [26], Pfizer
[27], Yale University Open Data Access (YODA) [28]
whilst others will also provide a route for researchers to
request the availability of a specific study (ies) e.g.
CSDR.com and YODA.
Step 2: Best practices for writing a patient level data
request research proposal
Many patient level data request systems have an elec-
tronic proposal form on their website that the researcher
needs to complete as part of the request process. Table 3
provides an outline of the types of information that may
be required. This outline may be a useful starter for
when there is no structured application form to fill in.
Tudur Smith et al. [11] and CSDR.com [26] provide de-
tailed examples of research request documentation.
The researcher should check if their institution or
country requires ethics approval for their proposed
work. It is the responsibility of the researcher to get eth-
ics approval and some Data Holders may ask for proof
of this as part of their review process.
The researcher should clearly identify the study (or
studies) required, preferably using the company unique
identifier. Some long running studies (e.g. in oncology
and other chronic disease settings like rheumatoid arth-
ritis) may have been analysed and reported for a number
of outcome measures and a number of timepoints and
as such multiple versions of the database and CSRs will
be on file. The request should include the database ver-
sion required as part of the proposal. If there is a specific
publication that was used to identify the study as being
required, include the publication detail. These details
will help the Data Holder’s data sharing support team to
identify the most appropriate dataset for you.
Not every item of “data” that has been collected within
the clinical trial will be available to share. Most compan-
ies will provide copies of the electronic database for the
study, but may not be able to share copies of the com-
pleted case report form pages, imaging data (e.g. x-ray
films or computed tomography (CT) scans) or genetic
data. Studies that are small (less than 50 patients) or
have been performed within a rare disease setting may
not be available for sharing if it is felt that in these set-
tings, the potential risks of patient identification are too
high. These requests will likely be considered on a case
by case basis.
A lay summary outlining the key intentions of the re-
search proposal is often required. For the CSDR.com
website [26] the lay summary of the research intent is
posted for public view whilst the analysis is actively on-
going. There are references [29–31] that provide advice
regarding writing lay text in the context of medical
research.
Step 3: Who decides whether your research proposal is
valid? The role of a review panel
The assessment of a research proposal requesting access
to patient level data has two aspects: is the study in
question considered to be available for sharing (the Data
Holder’s decision) and does the research proposal have
sufficient scientific merit (the Review Panel’s decision).
The Review Panel can be structured in a variety of ways.
At one extreme, Data Holders can choose to oversee
the review themselves by utilising employees of their
Table 3 Key components of a research request form
Proposal component Additional notes
Name and affiliation of the lead
researcher
Statement of the Scientific Goals of
the Research
Synopsis of Research Proposal Lay version may also be needed
Statistical Analysis Plan (SAP) Including endpoints to be evaluated, analytic methods to used and methods to control for bias in
post-hoc or data driven analyses. Should also state whether specific populations are to be analysed
e.g. effects of treatment in special patient groups
Studies for which data is requested Use unique study ID if known and database version required (if the study has been conducted over a long
period of time and has been analysed at different follow-up time points)
Include all studies to be combined including those obtained from other sources (e.g. studies completed by
your own institution)
Name and affiliation of other members
of the research team
There should be a professionally qualified statistician or confirmation that the proposed research team
has the relevant statistical expertise to perform and take responsibility for all statistical analyses should
be provided.
Some Data Holders require CVs or other information as reference.
Conflicts of interest Both real and potential
Source of Funding This is the funding source for the researcher.
Currently Data Holders do not require payment for the preparation and access to the patient level datasets.
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organisation to do this. Another approach is that they
use clinical trial experts outside their organisation to
perform this role. The three common types of Review
Panel are:
1. Internal Review Panel. All members are direct
employees of the Data Holder organisation. The
advantage of this approach is that the reviewers will
have a deep understanding of the product and
clinical trial(s) identified and whether the research
questions identified have been previously addressed
internally (though may not have been published).
The downside of this review approach is that the
board could be perceived as biased in approving
only research that is in keeping with the company’s
research interests.
2. External Review Panel (selected by the Data
Holder). Devolving approval decisions to a group of
experts outside the Data Holder’s immediate
organisation mitigates some of the concern for
biased decision making. However the fact that the
experts have been selected by the Data Holder and
will be paid directly by the Data Holder can lead to
criticism of their true independence.
3. External Review Panel (selected by a third
party). Using an independent third party (such as
the YODA and Janssen collaboration [28] or the
Wellcome Trust and clinicalstudydatarequest.com
collaboration [26]) for the selection and organisation
of the Review Board is the ideal for truly
independent decision making. In this model the
Data Holder would contract the third party to run
the Review Board and the third party would
contract experts of their choice to perform the
review. The Review Board members would not
receive any payments for their work from the Data
Holder directly but be paid for their time via the
third party.
Some Data Holders (e.g. Amgen [32], Pfizer [33]) have
opted for a hybrid approach whereby only those research
proposals that have been rejected by the internal review
board will subsequently be sent to an external panel for
a final assessment (mixture of approach 1 and 2 above).
The Review Board should be made up of a mixture of
disciplines. Ideal membership will include physicians
and at least one statistician and/or epidemiologist. There
may also be representation from medical ethicists, pa-
tient advocates and disease area specialists. The Chair of
the Review Board will generally be the final decision
maker.
Depending on the remit of the Review Board, the re-
view of the Research Proposal may vary from a high
level assessment of the research objectives and statistical
considerations to a detailed critique of the research in
the context of the current research thinking on that spe-
cific topic. Some companies make public the metrics for
the number of requests received and the number of Re-
view Board approvals and rejections [26, 28].
Step 4: Data holders’ expectations of researchers
Within the current data sharing systems Data Holders
cover the costs of generating the anonymized datasets,
collating the data package and paying the licences for
the controlled access systems that are used to provide
secure access to the data (if applicable). In return there
are a number of conditions that the researcher may be
required to commit to before being granted access to
the data. This may be encapsulated within a legally bind-
ing document called a Data Sharing Agreement (DSA)
or Data Use Agreement (DUA). As this is a legal docu-
ment the researcher may need to liaise with the Legal
Department at their research institution prior to signing.
Many of the data access request portals provide open ac-
cess to a copy of the DSA text for anyone to view and
download. The DSA step is frequently the slowest step
to gaining access to the data particularly in cases where
text changes are requested, as such it is recommended
that researchers contact their legal representatives early
in the process (e.g. at submission of the research pro-
posal) for advance warning and advice. The legal review
can take from a few days to many months if legal negoti-
ations are requested by the researcher.
The Data Sharing Agreement can include commitments
to:
a. have an appropriately qualified research team
b. ensure that the privacy and confidentiality of clinical
trial subjects will be safeguarded with no attempt to
establish their identities
c. publicly post the Research Proposal and Analysis
plan (ideally prior to the analysis being performed).
Some data sharing platforms provide this facility.
For systems where the Research Proposal plan is not
posted by the Data Holder, the Researcher could
post on their own academic institution's website.
d. only use the data to address the objectives outlined
in the Research Proposal and state that it will not be
used for any other purpose or shared with any third
party.
e. rapidly communicate any safety or efficacy issues to
regulators and Data Holder(s) if identified. For
example, if inconsistencies are found with the
original analysis.
f. publish results in a peer reviewed journal or other
public forum and provide a copy of the publication
to the Data Holder. Note some sponsors may
request the opportunity to provide a courtesy review
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prior to publication, but any comments or changes
suggested by the sponsor would not be binding.
g. attempt to complete research within a fixed time
period
Additionally, although not specifically covered in
the DSA, good analysis and programming practices
(as outlined in ICH E9 [34] and ENCePP Guide on
Methodological Standards in Pharmacoepidemiology
[35]) should be used.
Data holder’s commitments to researchers
Data Holders that have an internal review process for
data sharing requests should monitor the progress of the
review of research proposals submissions and seek to
minimise delays. Following the approval of a data shar-
ing request, the Data Holder should seek to generate the
datasets to be shared and accompanying documentation
in a reasonable period of time. The progress of generat-
ing the materials to be shared should be monitored to
minimise delays. Data Holders may have a central team
to manage all data sharing activities or individual project
teams may have to deliver on individual data sharing re-
sponsibilities. Irrespective of the framework being used,
Data Holders should ensure that the key stakeholders
within the organisation are aware of and trained in the
process to ensure full understanding of roles and re-
searcher’s expectations.
Step 5: How datasets are shared with researchers
There are a number of data access models that could be
considered by an organisation. Examples include:
Open access: Data is prospectively posted on to a
public website. Individual researchers can access these
data without having to go through a formal research re-
quest review process and they are able to download
datasets and hold copies on their own computers. An
example is the Immune Tolerance Network (ITN) Trial-
Share initiative [36].
Direct Sharing: Following approval of a data sharing
request, the Data Holder provides copies of de-identified
data directly to the Researcher. The Researcher contacts
the Data Holder directly and they agree to enable the re-
search. Datasets and documentation are sent directly to
the researcher (using secure file transfer protocol (SFTP)
or other secure electronic transfer system) so the re-
searcher is able to analyse the data on their own local
computer systems. An example is the Alzheimer’s Dis-
ease Neuroimaging Initiative (ADNI) [37].
Controlled access: Following review and agreement of
the research proposal by a review panel, data are
uploaded by the Data Holder into a secure website along
with supporting documentation. The researcher is given
access to the secure website and they perform all their
programming and analysis within the system. The re-
searcher is able to download analysis results but is not
able to download the datasets. There may be the facility
for the researcher to upload data and programs into the
secure website. Again a data sharing agreement may be
set up between the researcher and the Data Holder. Ex-
amples are YODA [28] and CSDR.com [26].
Many participants in clinical trials support the concept
of making data broadly available to maximize its scien-
tific value for future patients and this interest is driving
today’s data sharing principles. It is however the Data
Holder’s responsibility to maintain the security of clin-
ical trial subject’s personal information. Access models
like controlled access or third party analysis are pre-
ferred by the pharmaceutical industry, primarily as they
can best ensure patient data confidentiality [8]. Table 4
outlines these options and their pros and cons from both
the Researcher’s and Data Holder’s point of view. Open
access provides the most flexibilty for Researchers but
results in a high risk to patient confidentiality or results
in extensively anonymized data that will impact on data
useability. The other solutions outlined (direct sharing,
controlled access and third party analysis) require in-
creasing levels of complexity and time in order to gain
access to the data but will retain dataset useability as the
scale of necessary data anonymization will be less.
Example patient level data models for some pharmaceutical
industry data holders
Since the publication of the EFPIA/PhRMA principles
(July 2013), many pharmaceutical Data Holder organisa-
tions have published their data transparency policies on-
line. The EFPIA Clinical Trial Data Portal [7] is a quick
way to find information about a specific pharmaceutical
company and what they are willing to share and how to
request data. However, as companies continue to publish
and update their policies, the individual company web-
site will have the most accurate information regarding
the scope of their policy.
Pharmaceutical Data Holders have adopted a variety of
approaches to the mechanics of data requests. A number
of companies ask that you contact them directly, exam-
ples are AstraZeneca [38], Amgen [32], Merck [39],
Shire [40]) and Pfizer (via their INSPIIRE portal [33]).
Janssen and Bristol-Myers Squibb (BMS) have opted to
collaborate with an academic group – Janssen with Yale
University (called the YODA project [28]) and BMS with
Duke University [41]. In this model the academic group
is contracted to act as the gatekeeper for access to clin-
ical trial data by managing the request process, review
process and providing information and datasets to the
researcher (via secure access system) and liaison with
the researcher. Janssen and BMS staff provide the data
packages required by the researcher to the Yale and
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Immediate access for researchers. No pre-requisites needed regarding
qualifications or documentation of the research objectives and analysis
plan.
Data Holder:
No need for a research request and review process
Researchers:
No guarantee of direct access to the Data Holder if they encounter
difficulties in navigating the data or if they have questions regarding the
study conduct.
No knowledge of who else is accessing the data. Potential for
overlapping or repeated research questions arising from the same dataset
leading to increased chances of errors or increased type 1 errors.
Data Holder:
High risk to patient confidentiality as the data could be combined with
other datasets.
No traceability regarding who has accessed the data, whether they are
qualified in statistical analysis and how they have consequently used the
data.
As pre-specification of analysis is not needed nor monitored, there is a
risk for data dredging and over-interpretation of findings.
High internal costs if all trials are required to be anonymized and posted




No limitation on the statistical software that can be used.
Researcher:
Responsible for the security of any information held on their systems.
Easier to merge and combine data from a variety of sources. Potential impact on research credibility if collaboration by Researcher is
seen as not truly independent from the Data Holder.
Increased opportunity to address data and analysis questions with the
Data Holders’ study personnel.
Data Holder:
Potential for identifying synergies where the research is in keeping
with research interests of the organization. Potential opportunity to
collaborate with the Researcher and address any questions they have
during their research work.
Data Holder:
Security of the datasets is reliant on the security of the requesters
systems.
Reliant on the Researcher adhering to the terms of the DSA relating to
not sharing data outside the research group and only using the data for
research activities that have been approved. Without a DSA there is a risk
of data being misused.
Level of interaction between research and Data Holder project team




Ability to access data from multiple Data Holders in a defined process
Researcher:
Required to use only the analysis software supplied within the secure
website. May not be the software that they usually use, or with which
they are familiar leading to inconvenience and increased chance of
erroneous analysis.
Data Holder:
Datasets are supplied in a secure environment so the risk of patient
identification via merging with other datasets is reduced
The named researchers are the only ones who can interact with the
data.
Ability to compare pre-specified analyses versus published findings.
Able to share data with a wide range of researchers with less impact
on internal resourcing (compared to Open and Direct Sharing
approaches)
Commitments to publish/share their results with the Data Holder may be
required.
Concern that the work held on the system could be viewed by the Data
Holder.
Long term access may be tricky requiring archiving procedures.
May not be able to use data made accessible within a controlled
environment with data provided directly due to different Data Holder
sharing strategies.
Cannot be combined with controlled access data from other sources.
Data Holder:
Data are used for purposes beyond that outlined in the original access
request (controlled by data sharing agreement).
Cost to the sponsor for the website.
Relatively low resource intensity
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Duke teams respectively, but are not actively involved in
any decision making or communicating with the re-
searcher directly.
GSK launched a website for requesting access to GSK
trials (studies initiated on/after 2000) in May 2013. Since
then a number of companies have collaborated with
them to develop the clinicalstudydatarequest.com web-
site. This is a website which enables both single Data
Holder and multiple Data Holder requests to be submit-
ted. For example, if a Researcher requires access to clin-
ical trial data from GSK and Roche then they submit
one research proposal for all the studies identified, it is
reviewed by one Review Board, one Research Agreement
is signed and the data will be uploaded by each company
into the same area of the controlled access website.
Since August 2015 the Wellcome Trust has been re-
sponsible for the set-up and management of the inde-
pendent review component of the process [26].
Potential challenges of working with data from multiple
sources
The potential insights gained from access to data from
multiple Data Holders and from both failed and success-
ful studies will be of great benefit to medical under-
standing. This vision is not fully realised as yet as not all
trial sponsors have policies in place for access to patient
level data that includes failed trials or old trials.
Even if the trials that are needed are available the chal-
lenges the researcher will face when combining data
from different sources should not be underestimated.
Most studies will have been set up with few intentions
of combining across Data Holders, the case report form
questions, drug dictionaries, adverse event dictionaries
as well as the database structure itself will all need to be
assessed for feasibility of combining. The process of
merging data from different sources can take longer than
expected and a realistic view of the resource and time
needed should be factored into the Researcher’s plans.
In the future, the use of the Clinical Data Interchange
Standards Consortium (CDISC) [42] data structure prin-
ciples may go a long way to mitigate these problems
within pharmaceutical industry sponsored studies, but
fundamental differences in how questions have been
asked or subsequently coded on the case report forms
(CRF) will continue to be an issue unless CRF and corre-
sponding meta-data are made publicly available or
shared between sponsors and trialists [43].
Data package contents and researcher support
Typical dataset structure for pharmaceutical studies
The standard statistical software package that is used in
the pharmaceutical industry is SAS (Statistical Analysis
System), and as such the datasets from a clinical study
will tend to be in a SAS format. This is not the case for
non-Pharma sponsors of clinical trials who may use a
variety of different analysis software tools. When submit-
ting a new application or supplemental filing to the
FDA, the sponsor company is required to submit the
electronic patient level data for the studies in the sub-
mission such that the FDA Statistical Reviewer can re-
analyse the study and re-confirm key conclusions drawn
by the company. Standardization of dataset structures
for all data domains (e.g. demographic data, laboratory
data and adverse event data) and for specific disease
endpoints is the goal of the CDISC group [42]. However
we are still a long way from one consistent approach
across all organisations.
A “typical” clinical trial consists of a number of patient
visits and at each visit a number of medical assessments
will be made and recorded. This results in databases that
can hold thousands of datapoints for just one individual
subject. The standard approach is to create “raw” data-
sets that reflect the data as it was recorded on the case
report form and “analysis ready” datasets where all the
data derivations are generated. It is the “analysis ready”
datasets that are then used as the input to any statistical




Researcher does not require statistical analysis expertise in the team as
this will be provided by the third party.
Researcher:
Lack of direct interaction with the data could be frustrating. Reliant on a
positive collaboration with the third party analysts.
Able to focus his/her time on interpreting the analyses rather than in
data manipulation and programming.
Analysis work may be convoluted as there will need to be a lot of
interaction between the third party and the researcher.
Data Holder:
The analyses performed on the data is in keeping with the proposal
provided by the researcher. Reduced potential for unplanned,
additional data explorations.
Data Holder:
Cost implications. Not practical for small organisations. Increased chance
of mis-understanding of data structures and thus possible quality issues if
the Data Holder is not involved.
Analysis not considered to be independent as Data Holder owns the
contract with the third party.
Relatively low resource intensity but cost could be HIGH
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analyses and data summaries. The principles applied to
get from the raw data to the derived datapoints in an
analysis dataset will have been outlined in the Statistical
Analysis Plan (SAP) and Dataset Specifications. A “typ-
ical” phase 3 study can have between 15 and 20 datasets
(available as both raw and analysis versions) and can be
between 5 and 16 gigabytes in total.
In order to anonymise data, all data will be subject to
some editing (datapoints removed) and new patient
identifiers (compared to those used in the trial) will be
created in order to reduce the chance that an individual
will be identified from their clinical trial data. A number
of publications have discussed the issue of patient de-
identification [44–46] and we will not discuss it any
further here. The EFSPI/PSI Working Group article on
protecting patient confidentiality will cover best prac-
tices on this topic [47].
Step 6: Contents of a typical data package
Irrespective of the mode of data sharing (open, direct or
controlled), a researcher should expect to receive docu-
mentation to explain the contents of the datasets pro-
vided. Table 5 outlines the minimum information that
Data Holders should share with Researchers when access
to data is approved. The term “Data Package” is used to
describe all the information being shared and is made
up of both data and documents to help orientate the
Researcher around the datafiles. The documents should
include the study protocol, statistical analysis plan and
study report as well as more technical documentation.
Provision of SAS code and SASlogs are optional and less
likely to be included as part of the standard content.
Table 5 provides more detail about each of these
documents.
The IoM report calls for the sharing of the SAS code
that was used to generate the datasets and the analysis
results. Most companies do not currently share the
SAS code that was used as this will not be executable
easily on other SAS systems due to references to in-
house macros and other SAS standards. However de-
tails of the model/analysis statements used to generate
the analysis could be shared as they provide the re-
searcher with a good understanding of the model fitted
(e.g. random effects, interaction terms, and estimate
statements).
Step 7: Researcher support
It is acknowledged that researchers may need support
and advice when first navigating through the complex
dataset structures and materials.
Table 5 Possible Data Package Contents
Item Further details
Anonymized Raw datasets Dataset content reflects the information as recorded on the case report form. These are usually split into a number of
raw datasets reflecting the different types of data that have been collected, e.g. adverse events, laboratory




These datasets will have been derived from the raw datasets and will reflect the additional programming that needs
to be applied for the data to be analysis ready. This could be the synthesis of different datapoints to create a single
efficacy assessments (e.g. ACR score in RA or a time to disease progression) and could also include derivations and
assumptions as a result of missing data. They will also identify the original analysis populations (e.g. ITT, Per Protocol)
that were defined in the Statistical Analysis Plan. Researchers should understand the differences between these
populations so they can be used appropriately.
Protocol (including any
amendments)
The protocol describes the clinical study design, assessment schedule and planned statistical analysis in detail. Small
amounts of text may be subject to redaction if they are considered to be commercially confidential.
Annotated Case Report Form This document provides the link between the data points that were recorded by the investigator onto the paper or
electronic case report form and the variable name and dataset location where they are held within the database. This
is a key document to help the researcher navigate the database.
Statistical Analysis Plan This document is written by a statistician prior to the study data being available for analysis. It is a comprehensive
outline of the statistical endpoints to be derived and analysis methodology to be used. The 1 to 2 pages of statistical
detail from the protocol are expanded into a document that can be 10–20 pages in length.
Dataset specifications This (alongside the Statistical Analysis Plan) will provide a map of the dataset structure and data variable locations
Clinical Study Report The CSR will be subject to some redactions in order to preserve patients’ anonymity and in some cases to protect
commercially confidential information. The patient level data listings will not be included.
Optional: SAS Programs In situations where the analysis ready datasets cannot be found, sponsors may choose to share the SAS programs
that were used to create the derived datasets and analysis results. Note that copies of SAS programs may not be
executable on other systems without some editing.
In certain cases the SAS code outlining the statistical models used may be shared in order to help the researcher
navigate the data and original modelling approach.
Optional: SAS Logs Limited value as the original SAS program may not be executable on other computer systems or outside of the Data
Holder’s standard SAS macro calls.
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It is important to discuss the potential for further sup-
port from the Data Holders as the Researchers embark
on their work. Table 6 outlines the different scenarios
where discussion between the researcher and the Data
Holder may be needed or requested. This covers the
various stages in the research process when communica-
tion between the Researcher and Data Holder may be re-
quired, the types of questions and how they may be
implemented.
Most Data Holders will offer a support/question route
for the researcher. However this is likely to be limited to
questions about the data and will not be for more gen-
eral statistical analysis advice (e.g. How do I fit a certain
model in SAS?) or to provide clinical support.
For those companies sharing data via a controlled ac-
cess system such as the SAS Clinical Data Transparency
Tool ®, support will be provided for navigation and set
up by the provider of the tool.
Conclusions
This article addresses the key steps in requesting access to
patient level data and offers advice on how to navigate
through the request process. The key challenge that re-
mains for all researchers is discoverability of the trials that
have been conducted by both pharma and academia; until
there is 100 % compliance with the commitments around
registry postings this will continue to be an issue [19, 20].
Different data sharing models and platforms mean that
true cross product data collation is still not a reality.
However as most platforms (e.g. YODA, CSDR.com)
and companies (e.g. Pfizer) are all using the SAS Clinical
Trial Data Transparency Tool as the means to securely
share the datasets and documents, cross platform shar-
ing could be feasible in the future. Researchers are en-
couraged to make enquiries to trial sponsors in
situations where the studies required are available
through different platforms in order to see if a work-
around is possible.
The new era of access to patient level data is still in its
infancy and Data Holders and researchers continue to
learn from their experiences so far. Enhanced data ac-
cess holds the promise to increased scientific knowledge
and understanding whilst balancing the potential risks to
patient identification. At this time the benefits and chal-
lenges of patient level data sharing have not been fully
realised and we look forward to seeing how this new
world of transparency develops.
Summary
The objective of this article is to provide a primer for
academic researchers when accessing and working with
clinical trial data from other organisations. The main
points of consideration which are highlighted are for the
researcher to first find out what information is needed
and whether indeed patient level data is required. Once
the need for patient level data is established a recom-
mendation is given as to what a research proposal
should contain. The Researcher needs to understand the
Research Proposal review process, access commitments
and data access mechanism offered by the Data Holder..
Finally the expectations of the data holder are discussed
in terms of data sharing agreements and also what sup-
port can be made available to the researchers with
whom their data is being shared.
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data have been collected,
study design etc.
Possibility for Researchers to raise questions
directly regarding data collected on the data
sharing company sites.
Higher number of research proposals needing






Enable the Researcher to
understand data and the
analysis already
conducted.
Ensure complete documentation is provided
by data holder to eliminate this as much as
possible
Lack of knowledge of data collected









Sponsor requests to be informed up front of
publication. The alternative is to take a risk and
deal with receiving information in parallel to it
being in public domain
Differing results based on analyses of
anonymized data could lead to different
interpretation and raise either justifiable or
unnecessary concerns in scientific and public
domains
Sudlow et al. BMC Medical Research Methodology 2016, 16(Suppl 1):73 Page 34 of 43
council; MRCT, multi regional clinical trials center of Harvard and Brigham and
women’s hospital; NCT, number used as identifier in clinicaltrials.gov; PhRMA,
pharmaceutical research and manufacturers of America; PLD, patient level data;
PSI, statisticians in the pharmaceutical industry; RA, rheumatoid arthritis; SAP,
statistical analysis plan; SAS, statistical analysis system; SFTP, secure file transfer
protocol; TSC, trial steering committee; US, United States of America; WHO,
world health organisation; YODA, yale university open data access.
Acknowledgements
Thanks to Sally Hollis, Hans Ulrich Burger, Chrissie Fletcher, Nick Manamley,
Katherine Tucker, Christoph Gerlinger, Matthew Sydes, Zoe Williams, Maria
Dilleen and Sara Hughes for their review and input.
This article has been published as part of BMC Medical Research Methodology
Vol 16 Suppl 1, 2016: Data sharing in pharma. The articles have been through
the journal’s standard peer review process for supplements. The full content of
the supplement can be found at http://bmcmedresmethodol.biomedcentral.com/
articles/supplements/volume-16-supplement-1.
Funding
Publication of this article was funded by Roche.
Availability of data and materials
Not applicable.
Authors’ contributions
All authors are members of a working group formed by EFSPI (European
Federation of Statisticians in the Pharmaceutical Industry) and PSI
(Statisticians in the Pharmaceutical Industry) to examine various aspects of
transparency of patient-level data from clinical trials. All authors have a
statistical or statistical programming background. This article results from the
subgroup examining different models for providing access to patient level
data by third party researchers. All authors were involved in initial discussions
and planning over content, input to concepts and references, drafting of
initial versions, review and input to subsequent drafts and review and
approval of final content.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Author details
1Roche Products Limited, Welwyn Garden City, UK. 2Novartis Pharma AG,
Basel, Switzerland. 3University Medical Center, Goettingen, Germany. 4Ipsen
Biopharm (now Pharmaceutical Medicine Group, King’s College, London),
Slough, UK. 5Whately-Smith Limited, Kings Langley, UK.
Published: 8 July 2016
References
1. AllTrials Campaign. [http://www.alltrials.net]. Accessed 11 April 2016.
2. British Medical Journal Open Data Campaign. [http://www.bmj.com/open-data].
Accessed 11 April 2016.
3. European Medicines Agency. European Medicines Agency Draft policy on
publication and access to clinical-trial data. 24 June 2013 [http://www.ema.
europa.eu/docs/en_GB/document_library/Other/2013/06/WC500144730.pdf]
Accessed 11 April 2016.
4. European Federation of Pharmaceutical Industries and Associations (EFPIA)
and Pharmaceutical Research and Manufacturers of America (PhRMA).
Principles for responsible clinical trial data sharing: our commitment to
patients and researchers. 18 July 2013. [http://www.phrma.org/sites/default/
files/pdf/PhRMAPrinciplesForResponsibleClinicalTrialDataSharing.pdf].
Accessed 11 April 2016.
5. European Medicines Agency. European Medicines Agency policy on
publication of clinical data for medicinal products for human use. 2 Oct 2014.
[http://www.ema.europa.eu/docs/en_GB/document_library/Other/2014/10/
WC500174796.pdf]. Accessed 11 April 2016.
6. Fletcher C, Driessen S, Burger HU, Gerlinger C, Biesheuvel E. European
Federation of Statisticians in the Pharmaceutical Industry's position on
access to clinical trial data. Pharm Stat. 2013;12(6):333–6. doi:10.1002/pst.
1603. http://www.ncbi.nlm.nih.gov/pubmed/24136872.
7. European Federation of Pharmaceutical Industries and Associations. Clinical
Trial Data Portal Gateway [http://transparency.efpia.eu/responsible-data-
sharing/efpia-clinical-trial-data-portal-gateway]. Accessed 13 April 2016.
8. Institute of Medicine. Sharing clinical trial data: maximizing benefits,
minimizing risk. Washington, DC: The National Academies Press; 2015
[http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0080961/].
9. Varnai P, Rentel MC, Simmonds P, Sharp TA, Mostert B, de Jongh T.
Assessing the research potential of access to Clinical Trial Data. Report to
Wellcome Trust 2015 [http://www.wellcome.ac.uk/stellent/groups/
corporatesite/@msh_peda/documents/web_document/WTP058912.pdf].
Accessed 13 April 2016.
10. MRCT Center of Harvard and Brigham and Women’s Hospital. Proceedings
of Promoting Clinical Trial Data Transparency Conference. March 2015
[http://mrctcenter.org/wp-content/uploads/2015/11/2015-04-30_mrct_data_
transparency_conf_proceedings.pdf]. Accessed 13 April 2016.
11. Tudur Smith C, Hopkins C, Sydes M, Woolfall K, Clarke M, Murray G,
Williamson P. Good Practice Principles for Sharing Individual Participant
Data from Publicly Funded Clinical Trials. Version 1, Apr 2015. [http://www.
methodologyhubs.mrc.ac.uk/files/7114/3682/3831/
Datasharingguidance2015.pdf] Accessed 13 April 2016.
12. European Medicines Agency. External guidance on the implementation of
the European Medicines Agency policy on the publication of clinical data
for medicinal products for human use. 2 March 2016. [http://www.ema.
europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_
guideline/2016/03/WC500202621.pdf] Accessed 11 March 2016.
13. US Office for Civil Rights (OCR). Guidance Regarding Methods for
De-identification of Protected Health Information in Accordance with the
Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule. 26
Nov 2012. [http://www.hhs.gov/sites/default/files/ocr/privacy/hipaa/
understanding/coveredentities/De-identification/hhs_deid_guidance.pdf]
Accessed 11 March 2016.
14. Doshi P, Jefferson T. Clinical study reports of randomised controlled trials:
an exploratory review of previously confidential industry reports. BMJ Open.
2013;3:e002496. doi:10.1136/bmjopen-2012-002496. http://www.ncbi.nlm.
nih.gov/pubmed/23447465.
15. Higgins JPT, Green S. (editors). Cochrane Handbook for Systematic Reviews of
Interventions Version 5.1.0. The Cochrane Collaboration, 2011. [http://handbook.
cochrane.org/]. Accessed 13 April 2016. [http://www.ncbi.nlm.nih.gov/pmc/
articles/PMC3196245/]
16. ClinicalTrials.gov [https://clinicaltrials.gov/] Accessed 13 April 2016.
17. EUdraCT public website [https://eudract.ema.europa.eu/index.html]
Accessed 13 April 2016.
18. WHO International Clinical Trials Registry Platform [http://www.who.int/
ictrp/en/] Accessed 13 April 2016.
19. Anderson M, Chiswell K, Peterson E, Tasneem A, Topping M, Califf R.
Compliance with Results Reporting at ClinicalTrials.gov. N Engl J Med. 2015;
372:1031–9. doi:10.1056/NEJMsa1409364. http://www.ncbi.nlm.nih.gov/
pubmed/25760355.
20. Miller JE, Korn D, Ross JS. Clinical trial registration, reporting, publication and
FDAAA compliance: a cross-sectional analysis and ranking of new drugs
approved by the FDA in 2012. BMJ Open. 2015;5:e009758. doi:10.1136/
bmjopen-2015-009758 [http://bmjopen.bmj.com/content/5/11/e009758.full].
21. FDA Approved Drug Products [http://www.accessdata.fda.gov/scripts/cder/
drugsatfda/] Accessed 13 April 2016.
22. European Medicines Agency. European Public Assessment Reports.
[http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/
epar_search.jsp&mid=WC0b01ac058001d124]. Accessed 11 April 2016.
23. GSK Press Release 22 April 2014 [http://us.gsk.com/en-us/media/press-
releases/2014/gsk-announces-major-3-part-transaction-with-novartis-to-
drive-sustainable-sales-growth-improve-long-term-earnings-and-deliver-
increasing-returns-to-shareholders/]. Accessed 13 April 2016.
24. Krumholz H, Gross C, Blount K, Ritchie J, Hodshon B, Lehman R, Ross J. Sea
change in open science and data sharing: leadership by industry. Circ
Cardiovasc Qual Outcomes. 2014;7(4):499–504. doi:10.1161/CIRCOUTCOMES.
114.001166. http://www.ncbi.nlm.nih.gov/pubmed/24891590.
25. Conroy E, Harman N, Lane J, Lewis S, Murray G, Norrie J, Sydes M, Gamble
C. Trial Steering Committees in randomised controlled trials: A survey of
Sudlow et al. BMC Medical Research Methodology 2016, 16(Suppl 1):73 Page 35 of 43
registered clinical trials units to establish current practice and experiences.
Clin Trials. 2015;12(6):664–76. doi:10.1177/1740774515589959. http://www.
ncbi.nlm.nih.gov/pubmed/26085545.
26. Clinical Study Data Request.com. [https://www.clinicalstudydatarequest.
com/]. Accessed 13 April 2016.
27. Pfizer. Data Access Requests. [http://www.pfizer.com/research/clinical_trials/
trial_data_and_results/data_requests]. Accessed 13 April 2016.
28. The Yale University Open Data Access (YODA) Project. [http://yoda.yale.edu/
]. Accessed 13 April 2016.
29. Cochrane Collaboration. Standards for the reporting of Plain Language
Summaries in new Cochrane Intervention Reviews (PLEACS) Version 3.0
[http://editorial-unit.cochrane.org/sites/editorial-unit.cochrane.org/files/
uploads/PLEACS_0.pdf]. Accessed 13 April 2016.
30. MRCT Center of Harvard and Brigham and Women’s Hospital. Return of
aggregate results. [http://mrctcenter.org/return-results]. Accessed 13
April 2016.
31. British Library. Writing about biomedical and health research in plain
English: A guide for authors. [http://www.access2understanding.org/wp-
content/uploads/2014/11/Access-to-Understanding-writing-guidance_v1.
pdf] Accessed 11 April 2016.
32. Amgen. Clinical Trial Transparency, Data Sharing and Disclosure Practices.
[http://www.amgen.com/about/data_sharing.html]. Accessed 15 April 2016.
33. Pfizer. Transparency of clinical trial data. [http://www.pfizer.co.uk/content/
transparency-clinical-trial-data] Accessed 15 April 2016.
34. ICH E9 Expert Working Group. Statistical principles for clinical trials: ICH
harmonized tripartite guideline. Stat Med. 1999;18(15):1905–42. [doi: 10.
1002/(SICI)1097-0258(19990815)18:15<1903::AID-SIM188>3.0.CO;2-F] [http://
www.ncbi.nlm.nih.gov/pubmed/10532877]
35. The European Network of Centres for Pharmacoepidemiology and
Pharmacovigilance (ENCePP). Guide on methodological standards in
pharmacoepidemiology (Revision 4). EMA/95098/2010. [http://www.encepp.
eu/standards_and_guidances/documents/
ENCePPGuideofMethStandardsinPE_Rev4.pdf] Accessed 15 April 2016.
36. Immune Tolerance Network. TrialShare. [http://www.immunetolerance.org/
node/1121]. Accessed 15 April 2016.
37. Alzheimer’s Disease Neuroimaging Initiative (ADNI). Sharing Alzheimer's
research data with the world. [http://adni.loni.usc.edu/] Accessed 15
April 2016.
38. AstraZeneca Group of Companies. Data request portal. [https://astrazenecagroup-
dt.pharmacm.com/DT/Home]. Accessed 15 April 2016.
39. Merck. Company procedure on access to clinical trial data. [http://www.
merck.com/clinical-trials/pdf/Procedure_on_access_to_clinical_trial_data_
2016.pdf]. Accessed 15 April 2016.
40. Shire. Our commitment to transparency. [http://www.shiretrials.com/en/our-
commitment-to-transparency]. Accessed 15 April 2016.
41. Bristol-Myers Squibb. Disclosure commitment. [http://bms.com/clinical_trials/
pages/disclosure.aspx]. Accessed 15 April 2016.
42. Clinical Data Interchange Standards Consortium. CDISC mission and principles.
[http://www.cdisc.org/CDISC-Vision-and-Mission]. Accessed 15 April 2016.
43. Dugas M, Jöckel K-H, Friede T, Gefeller O, Kieser M, Marschollek M,
Ammenwerth E, Röhrig R, Knaup-Gregori P, Prokosch H-U. Memorandum
“Open Metadata”: Open access to documentation forms and item catalogs
in healthcare. Methods Inform Med. 54: 376–8. doi: 10.3414/ME15-05-0007.
[http://www.ncbi.nlm.nih.gov/pubmed/26108979].
44. Hrynaszkiewicz I, Norton M, Vickers A, Altman D. Preparing raw clinical data
for publication: guidance for journal editors, authors, and peer reviewers.
BMJ. 2010;340:c181. doi:10.1136/bmj.c181. http://www.ncbi.nlm.nih.gov/
pubmed/20110312.
45. Hughes S, Wells K, McSorley P, Freeman A. Preparing individual patient data
for clinical trials for sharing: the GlaxoSmithKline approach. Pharm Stat.
2014;13(3):179–83. doi:10.1002/pst.1615. http://www.ncbi.nlm.nih.gov/
pubmed/24668938.
46. TransCelerate Biopharma Inc. Data de-identification and anonymization of
individual patient data in clinical studies – a model approach. [http://www.
transceleratebiopharmainc.com/wp-content/uploads/2015/04/Data-
Anonymization-Paper-FINAL-5.18.15.pdf] Accessed 16 April 2016.
47. Tucker K, Branson J, Dilleen M, Hollis S, Loughlin P, Dixon MJ, Williams Z.
Protecting patient privacy when sharing patient-level data from clinical
trials. BMC Med Res Methodol. 2016 (accepted for publication).
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Sudlow et al. BMC Medical Research Methodology 2016, 16(Suppl 1):73 Page 36 of 43
